Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT ID: NCT00159120
Last Updated: 2008-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
71 participants
INTERVENTIONAL
2001-11-30
2006-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
further maintenance antipsychotic treatment and prodrome-based early intervention
maintained antipsychotic treatment vs. stepwise drug discontinuation
maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
2
stepwise drug discontinuation (after 1 year maintenance antipsychotic treatment) and prodrome-based early intervention
maintained antipsychotic treatment vs. stepwise drug discontinuation
maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
maintained antipsychotic treatment vs. stepwise drug discontinuation
maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 18 and 55
* Informed consent
* One year neuroleptic maintenance treatment
* Reaching stable course
Exclusion Criteria
* Legal reasons
* Insufficient knowledge of the german language
* Substance abuse or addiction
* Pregnancy
* Serious physical illness
* Organic brain disease
* Contraindication to neuroleptic treatment
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Federal Ministry of Education and Research
OTHER_GOV
German Research Network On Schizophrenia
NETWORK
Janssen-Cilag Ltd.
INDUSTRY
University of Bonn
OTHER
Humboldt-Universität zu Berlin
OTHER
Ludwig-Maximilians - University of Munich
OTHER
University of Göttingen
OTHER
University of Cologne
OTHER
Mainz University
OTHER
University Hospital Tuebingen
OTHER
Universität Duisburg-Essen
OTHER
University of Mannheim
OTHER
University of Jena
OTHER
Martin-Luther-Universität Halle-Wittenberg
OTHER
RWTH Aachen University
OTHER
University of Wuerzburg
OTHER
Heinrich-Heine University, Duesseldorf
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wolfgang Gaebel, Professor
Role: STUDY_CHAIR
Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University of Düsseldorf, Rhineland State Clinics Düsseldorf, Bergische Landstraße 2, 40629 Düsseldorf, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
German Research Network on Schizophrenia, Department of Psychiatry and Psychotherapy at the Heinrich-Heine-University Düsseldorf
Düsseldorf, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gaebel W, Moller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wolwer W, Von Wilmsdorff M, Bottlender R, Klingberg S. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):129-40. doi: 10.1007/s00406-004-0509-y.
Seemuller F, Schennach R, Mayr A, Musil R, Jager M, Maier W, Klingenberg S, Heuser I, Klosterkotter J, Gastpar M, Schmitt A, Schlosser R, Schneider F, Ohmann C, Lewitzka U, Gaebel W, Moller HJ, Riedel M; German Study Group on First-Episode Schizophrenia. Akathisia and suicidal ideation in first-episode schizophrenia. J Clin Psychopharmacol. 2012 Oct;32(5):694-8. doi: 10.1097/JCP.0b013e3182677958.
Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H, Riedel M, Klingberg S, Kopcke W, Ohmann C, Moller HJ; German Study Group on First-Episode Schizophrenia. Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011 Feb;72(2):205-18. doi: 10.4088/JCP.09m05459yel. Epub 2010 Jun 29.
Related Links
Access external resources that provide additional context or updates about the study.
Click here for more information about this study: Pharmacological long-term treatment strategies for relapse prevention in first episode schizophrenia
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01GI 9932 - P 2.2.2.1 / 2
Identifier Type: -
Identifier Source: org_study_id